A Randomized, Double-Blind, Active-Controlled, Phase 3 Extension Study Investigating the Safety and Efficacy Over 40 Weeks of 2 Doses of MAP0010 [budesonide] in Asthmatic Children (12 Months to 8 Years Old at the Time of Enrollment Into the MAP0010-CL-P301 Study)

Trial Profile

A Randomized, Double-Blind, Active-Controlled, Phase 3 Extension Study Investigating the Safety and Efficacy Over 40 Weeks of 2 Doses of MAP0010 [budesonide] in Asthmatic Children (12 Months to 8 Years Old at the Time of Enrollment Into the MAP0010-CL-P301 Study)

Discontinued
Phase of Trial: Phase III

Latest Information Update: 29 Jan 2014

At a glance

  • Drugs Budesonide (Primary)
  • Indications Asthma
  • Focus Adverse reactions; Registrational
  • Sponsors MAP Pharmaceuticals
  • Most Recent Events

    • 18 Nov 2009 Actual patient number (192) added as reported by ClinicalTrials.gov.
    • 18 Nov 2009 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 23 Jan 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top